The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The collaboration will center on expanding access to Eastman’s Esmeri technology
Subscribe To Our Newsletter & Stay Updated
